FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 144 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR New drug available for rare thyroid cancer on NHS in England October 1, 2021 Cancer in My Community: How People With Cancer Access Care in... August 12, 2021 Three-Drug Regimen Improves Protection against GVHD after Stem Cell Transplant July 14, 2023 Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... July 28, 2025 Load more HOT NEWS Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... Could Bacteria Help Find Cancer? Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions
